Memantine in systemic lupus erythematosus: a randomized, double-blind placebo-controlled trial.

ABSTRACT:

Objectives

Cognitive impairment affects up to 80% of systemic lupus erythematosus (SLE) patients within 10 years of diagnosis. Memantine, a seronergic receptor and nicotine acetylcholine receptor antagonist, acts on the glutamatergic system through the NMDA receptor and is used to treat dementia. We investigated whether it had benefit for SLE cognitive impairment.

Methods

A randomized double-blind, placebo-controlled single-center 12-week trial of memantine titrated to 20 mg/d was performed, using a 2:1 randomization ratio, in 51 SLE patients. The primary outcome measures were change in the Automated Neuropsychological Assessment Metrics throughput scores at 12 weeks.

Results

There were no statistically significant differences between treatment groups or change from b

SUBMITTER: Petri M 

PROVIDER: S-EPMC3153605 | biostudies-literature | 2011 Oct

REPOSITORIES: biostudies-literature